Literature DB >> 2357082

Intelligence and quality of dietary treatment in phenylketonuria.

I Smith1, M G Beasley, A E Ades.   

Abstract

The records of the Phenylketonuria Register were examined to determine the factors associated with early intellectual progress in children who had received a diet low in phenylalanine from soon after birth. A total of 1031 children were born between 1964 and 1980 and started treatment before they were 4 months of age, and 808 of them were followed up prospectively. In 263 children born between 1964 and 1971 (cohort 1), the mean intelligence quotient (IQ) at 4 years rose with year of birth from 24 points below revised IQ norms to 10 points below; in 545 born between 1972 and 1980 (cohort 2) there was no further rise in IQ and the mean remained eight points below the norms. IQ fell progressively by roughly four points for each four weeks' delay in starting treatment, for each 300 mumol/l rise in mean phenylalanine concentrations during treatment, and for each five months during the first two years during which phenylalanine concentrations were below 120 mumol/l. Forty six children in cohort 2 had the most favourable treatment characteristics. Their mean IQ, after standardising for social class, was 112.6, and similar to the mean for the same group estimated by multiple regression, and to revised population IQ norms for the period during which the children were tested. The data suggest that many children who are treated early continue to suffer a mild degree of neurological impairment because of the difficulties in fully controlling the metabolic abnormality.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2357082      PMCID: PMC1792169          DOI: 10.1136/adc.65.5.472

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  Intellectual performance of 36 phenylketonuria patients and their nonaffected siblings.

Authors:  J C Dobson; E Kushida; M Williamson; E G Friedman
Journal:  Pediatrics       Date:  1976-07       Impact factor: 7.124

2.  Evaluation of treatment begun in first three mohs oflife in 184 cases of phenylketonuria.

Authors:  F P Hudson; V L Mordaunt; I Leahy
Journal:  Arch Dis Child       Date:  1970-02       Impact factor: 3.791

Review 3.  Phenylketonuria: 50 years since Følling's discovery and still expanding our clinical and biochemical knowledge.

Authors:  F Güttler
Journal:  Acta Paediatr Scand       Date:  1984-11

4.  Intelligence and behaviour in children with early treated phenylketonuria. A report from the MRC/DHSS phenylketonuria register.

Authors:  I Smith; M Beasley
Journal:  Eur J Clin Nutr       Date:  1989       Impact factor: 4.016

5.  Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age.

Authors:  R Koch; C Azen; E G Friedman; M L Williamson
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

6.  Early-treated phenylketonuria: neuropsychologic consequences.

Authors:  R L Brunner; M K Jordan; H K Berry
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

7.  Correlates of intelligence test results in treated phenylketonuric children.

Authors:  M L Williamson; R Koch; C Azen; C Chang
Journal:  Pediatrics       Date:  1981-08       Impact factor: 7.124

8.  Neuropsychological deficits in early treated phenylketonuric children.

Authors:  B F Pennington; W J van Doorninck; L L McCabe; E R McCabe
Journal:  Am J Ment Defic       Date:  1985-03

9.  Intellectual assessment of 111 four-year-old children with phenylketonuria.

Authors:  J C Dobson; M L Williamson; C Azen; R Koch
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

10.  Collaborative study of children treated for phenylketonuria: study design.

Authors:  M Williamson; J C Dobson; R Koch
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

View more
  54 in total

Review 1.  Rare diseases and the assessment of intervention: what sorts of clinical trials can we use?

Authors:  B Wilcken
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

2.  Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

Review 3.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

4.  Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test.

Authors:  P Griffiths; R Campbell; P Robinson
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

5.  Audit of neonatal screening programme for phenylketonuria and congenital hypothyroidism.

Authors:  N Simpson; R Randall; S Lenton; S Walker
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

6.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

7.  Intelligence in mild atypical phenylketonuria.

Authors:  P M Costello; M G Beasley; S L Tillotson; I Smith
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

8.  Hyperphenylalaninaemia and outcome in intravenously fed preterm neonates.

Authors:  A Lucas; B A Baker; R M Morley
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

9.  Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse.

Authors:  F A Hommes; L Moss
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

10.  Untreated non-phenylketonuric-hyperphenylalaninaemia: intellectual and neurological outcome.

Authors:  J Weglage; K Ullrich; M Pietsch; B Fünders; R Zass; H G Koch
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.